Adrenal atrophy physical examination

Revision as of 03:30, 5 February 2022 by Maryam Hadipour (talk | contribs)
Jump to navigation Jump to search

Adrenal atrophy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenal atrophy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Adrenal atrophy physical examination On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenal atrophy physical examination

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenal atrophy physical examination

CDC on Adrenal atrophy physical examination

Adrenal atrophy physical examination in the news

Blogs on Adrenal atrophy physical examination

Directions to Hospitals Treating Adrenal atrophy

Risk calculators and risk factors for Adrenal atrophy physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]

Overview

In the physical examination the patients may have hypotension, hyperpigmentation, depigmentation in autoimmune cases.

Physical examination

In the physical examination the patients may have:

  • Hypotension, mainly with postural dizziness or syncope.
  • Hyperpigmentation, which is evident in nearly all patients with primary adrenal insufficiency, is the most characteristic physical finding.
  • Patchy, often bilaterally symmetrical areas of depigmented skin (vitiligo), the result of autoimmune destruction of dermal melanocytes, occur on the trunk or extremities in 10 to 20 percent of patients
with autoimmune but not those with other causes of adrenal atrophy.[1][2]

References

  1. Abdu TA, Elhadd TA, Neary R, Clayton RN (March 1999). "Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease". J Clin Endocrinol Metab. 84 (3): 838–43. doi:10.1210/jcem.84.3.5535. PMID 10084558.
  2. Husebye ES, Perheentupa J, Rautemaa R, Kämpe O (May 2009). "Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I". J Intern Med. 265 (5): 514–29. doi:10.1111/j.1365-2796.2009.02090.x. PMID 19382991.

Template:WH Template:WS